

Xstrahl News: August 2010

Gulmay medical becomes Xstrahl to reflect expansion into the scientific research arena

Benefitting medical practitioners, patients and researchers

Gulmay Medical, a designer and manufacturer of a world-renowned range of superficial and orthovoltage radiotherapy systems that have been essential in supporting healthcare professionals and their patients in over 500 clinics for the past 15 years, has announced that it is becoming Xstrahl Limited, effective immediately. This move will consolidate the company's broad portfolio, enabling radiation therapy and pioneering research as well as the commercialization of the SARRP research platform. SARRP is the most advanced X-ray system delivering a state-of-the-art Image Guided Micro-Irradiation (IGMI) technique for preclinical and radiation biology research.

Xstrahl's SARRP research platform is transforming our understanding of radiation therapy, a treatment that is employed in over 50% of cancer patients worldwide, as well as providing the most advanced preclinical platform for validating the efficacy of advanced radiation therapies. In addition, Xstrahl has facilitated *in vitro* and *in vivo* radiation based research studies by providing a range of X-ray irradiation cabinets.

Martin Robinson, Managing Director says, "Xstrahl more accurately reflects our new positioning as a provider of complete and specialist clinical solutions that will benefit medical practitioners, their patients and researchers. A key driver in enabling us to make these advancements has been the Xstrahl team's unique, in-depth understanding of X-ray therapy techniques in the clinical environment and expertise in designing and building X-Ray Medical and Research Systems."

Xstrahl has launched a new website that showcases its clinical and research radiotherapy offerings. Further details can be found at: www.xstrahl.com.

Contacts:

College Hill

Tony Stephenson or Gemma Howe
+ 44 207 866 7860
xstrahl@collegehill.com

Xstrahl

Martin Robinson
+44 1276 66266